Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

In the pivotal TEMPO 3:4 trial, the arginine vasopressin V2‐receptor antagonist tolvaptan reduced the rate of kidney growth in patients with autosomal dominant polycystic kidney disease. Tolvaptan was initiated as daily morning/afternoon doses of 45/15 mg, and uptitrated weekly to 60/30 mg and 90/30...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoaf, Susan E., Chapman, Arlene B., Torres, Vicente E., Ouyang, John, Czerwiec, Frank S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacokinetics/Pharmacodynamics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480307/
https://www.ncbi.nlm.nih.gov/pubmed/28218410
http://dx.doi.org/10.1002/jcph.880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480307/
https://www.ncbi.nlm.nih.gov/pubmed/28218410
http://dx.doi.org/10.1002/jcph.880

Ejemplares similares